Skip to main content
University of Washington Health Sciences Library

CI # 51577 Does the concurrent use of clopidogrel and proton pump inhibitors pose clinically significant thromboembolic risks in patients treated for acute coronary syndrome?: search

Search Summary

Cochrane Library - CDSR (Systematic Reviews)

0 clopidogrel and proton pump inhibitors
PubMed

Systematic reviews & meta analyses

22 (cardiovascular diseases[mh] OR acute coronary syndrome*[tw] OR coronary artery disease[tiab]) AND (platelet aggregation inhibitors[mh] OR clopidogrel) AND (proton pump inhibitors[mh] OR proton pump inhibitors[pa] OR proton pump inhibitor*[tiab] OR pantoprazole* OR omeprazole* OR esomeprazole* OR lansoprazole* OR rabeprazole* OR timoprazole) AND (Meta Analysis[pt] OR meta analy*[ti] OR metaanaly*[ti] OR systematic review*[ti] OR data synthesis[tw] OR data extraction[tw] OR Cochrane Database Syst Rev[ta]) AND english[la]
Cochrane Library - DARE: Other Systematic Reviews 2

Safety of clopidogrel‐proton pump inhibitors combination therapy on cardiovascular events: a systematic review. Provisional abstract for original article: Kuang JY, Tan J, Zou JJ, Chen SL. Chinese Journal of Evidence‐Based Medicine.2011;11(3):283‐291.

Effects of proton pump inhibitors on platelet function in patients receiving clopidogrel: A systematic review. Provisional abstract for original article: Kwok CS, Loke YK.  Drug Safety.2012;35(2):127‐139.

PubMed

RCTs; duplicates removed

54 (cardiovascular diseases[mh] OR acute coronary syndrome*[tw] OR coronary artery disease[tiab]) AND (platelet aggregation inhibitors[mh] OR clopidogrel) AND (proton pump inhibitors[mh] OR proton pump inhibitors[pa] OR proton pump inhibitor*[tiab] OR pantoprazole* OR omeprazole* OR esomeprazole* OR lansoprazole* OR rabeprazole* OR timoprazole) AND (randomized controlled trial[pt] OR ((random*[tw] AND trial*[tw]) NOT medline[sb])) NOT (Meta Analysis[pt] OR meta analy*[ti] OR metaanaly*[ti] OR systematic review*[ti] OR data synthesis[tw] OR data extraction[tw] OR Cochrane Database Syst Rev[ta]) AND english[la]
PubMed

Guidelines

7 (cardiovascular diseases[mh] OR acute coronary syndrome*[tw] OR coronary artery disease[tiab]) AND (platelet aggregation inhibitors[mh] OR clopidogrel) AND (proton pump inhibitors[mh] OR proton pump inhibitors[pa] OR proton pump inhibitor*[tiab] OR pantoprazole* OR omeprazole* OR esomeprazole* OR lansoprazole* OR rabeprazole* OR timoprazole) AND (Guideline[pt] OR Practice Guideline[pt] OR Consensus Development Conference[pt] OR Consensus Development Conference, NIH[pt] OR ((consensus[ti] OR guideline*[ti] OR guidance[ti]) NOT medline[sb]))
National Guideline Clearinghouse  

Diagnosis and treatment of chest pain and acute coronary syndrome (ACS). Institute for Clinical Systems Improvement (ICSI); 2012 Nov.

Primary and secondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. 2012. American College of Chest Physicians.

Secondary prevention of ischemic heart disease and stroke in adults. 2014. University of Michigan Health System.

MI - secondary prevention. Secondary prevention in primary and secondary care for patients following a myocardial infarction. 2013. National Institute for Health and Care Excellence (NICE).

2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

FPIN CIs, PURLS, HDAs   What is the clinical significance of the interaction of clopidogrel and PPIs? Evidence-Based Practice. 15(11): 9-10.

Author Information

Clinician Authors: Jason Baker, Sandy Shehata and Gary Kelsberg

Librarian:  Sarah Safranek

Search Due Date: Nov 2017

Manuscript Due Date:

Contact and Questions

Ordering Articles/Books

Librarian Contact Information:

Sarah Safranek, MLIS
Information Management Librarian
safranek@uw.edu
guides.lib.uw.edu/hsl/safranek

Health Sciences Library | 1959 NE Pacific Street, T334 Health Sciences Building, Box 357155, Seattle, WA 98195-7155 USA, 206-543-3390 | Privacy | Terms